Total Funding
85
79
Total FundingPost-IPO Debt raised
Growth Score
-4 pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
1602
Gilead Sciences develops and markets biopharmaceutical therapies, focusing on antiviral, oncology, and inflammatory diseases.
- Gary Tully: Head of Legal Operations
- Brian Peters: Executive Director and Head of Procurement Services & Delivery
About the Company
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines to address unmet medical needs. With each discovery and experimental drug candidate, they seek to improve the care of patients suffering from life-threatening diseases.
Gilead's primary areas of focus include
HIV/AIDS, liver disease, and serious cardiovascular and respiratory conditions.
